Results 61 to 70 of about 4,104 (188)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity

Diabetes, Obesity and Metabolism, Volume 27, Issue S2, Page 20-34, April 2025.
ABSTRACT Background The prevalence of obesity and related co‐morbidities has reached epidemic proportions. Effective evidence‐based treatment approaches are therefore important. Lifestyle intervention remains the mainstay of the treatment strategy to manage obesity.
Iskandar Idris, Oluwaseun Anyiam
wiley   +1 more source

Real-life data on pasireotide in monotherapy or combined in active Cushing’s disease

Frontiers in Endocrinology
IntroductionIn the last few years, the use of medical treatment in Cushing’s disease (CD) has increased thanks to the availability of new molecules. Nevertheless, real-life data on combination treatments are still lacking.MethodsThis is a retrospective ...
Alessandro Mondin, Alessandro Mondin, Filippo Ceccato, Filippo Ceccato, Carla Scaroni, Carla Scaroni, Luca Denaro, Renzo Manara, Renzo Manara, Umberto Maria Robertazzo, Umberto Maria Robertazzo, Mattia Barbot, Mattia Barbot   +12 more
doaj   +1 more source

A Five‐Year Journey to Diagnosis: Resolving Persistent Hypoglycemia Through Successful Insulinoma Resection—A Case Report

Clinical Case Reports, Volume 13, Issue 3, March 2025.
ABSTRACT Insulinoma is a rare functional pancreatic neuroendocrine tumor with an annual prevalence of 0.5–5 cases per million. It is characterized by excessive insulin secretion, leading to recurrent hypoglycemia, often diagnosed through Whipple's triad: hypoglycemic symptoms, documented low plasma glucose, and symptom resolution after glucose ...
Ankit Shrestha, Anup Pandey, Paleswan Joshi Lakhey, Biraj Baral, Aakash Pandit, Achyut Marahatta, Amisha Seth   +6 more
wiley   +1 more source

Managing Hypoglycaemia in Patients With Insulinoma—A Tertiary Centre Experience and Review of the Literature

Clinical Endocrinology, Volume 102, Issue 3, Page 344-354, March 2025.
ABSTRACT The management of hypoglycaemia is pivotal in the care of patients with insulinoma. Blood glucose monitoring and regulation needs careful attention pre‐ and peri‐operatively for patients undergoing surgical resection and as part of the long‐term management for patients with inoperable or metastatic disease.
Sophie Howarth, Tak‐Wai Ho, James Wimbury, Ruth Casey   +3 more
wiley   +1 more source

Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly

JCEM Case Reports
We report a case of interstitial nephritis, likely secondary to oxalate nephropathy, due to the development of pancreatic exocrine dysfunction after commencement of pasireotide for acromegaly. Pasireotide is known to impair insulin secretion but can also
Annabelle G Hayes, Mark J Penny, K. Aivazian, Jerry R Greenfield   +3 more
semanticscholar   +1 more source

Grading and staging for pituitary neuroendocrine tumors

Brain Pathology, Volume 35, Issue 1, January 2025.
Abstract Pituitary adenoma/pituitary neuroendocrine tumors (PitNETs) are the second most common primary intracranial tumor and the most frequent neuroendocrine tumors/neoplasms of the human body. Thus, they are one of the most frequent diagnoses in neuropathologist's practise.
Chiara Villa, Maria Francesca Birtolo, Luis Gustavo Perez‐Rivas, Alberto Righi, Guillaume Assie, Bertrand Baussart, Sofia Asioli   +6 more
wiley   +1 more source

The place of pasireotide in precision treatment of patients with acromegaly

Meditsinskiy sovet = Medical Council
Due to the syndromal nature of acromegaly, the effectiveness of its treatment depends on the consideration of age, clinical and pathomorphological features of the disease, which determine the logistics of the selection of personalized therapeutic ...
E. V. Pronin, T. M. Alexeeva, V. Pronin, M. B. Antsiferov   +3 more
semanticscholar   +1 more source

Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective

Brain Pathology, Volume 35, Issue 1, January 2025.
This article reviews the major biological characteristics of somatostatin receptors (SST2 and SST5) in anterior pituitary tumors, and the immunohistochemical evaluation of their expression as predictors of response to pharmacological therapy with SST ligands.
Laura Botelho, Rômulo Sperduto Dezonne, Luiz Eduardo Wildemberg, Renan Lyra Miranda, Mônica R. Gadelha, Felipe Andreiuolo   +5 more
wiley   +1 more source

Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas

Immunity, Inflammation and Disease, Volume 12, Issue 12, December 2024.
ABSTRACT Background The overwhelming majority of pituitary tumors consist of pituitary adenomas (PAs), which have recently also been termed pituitary neuroendocrine tumors (PitNETs). Clinically significant PAs occur in approximately one in every 1000 individuals, while other types of pituitary tumors, such as craniopharyngiomas and pituicytomas, are ...
Dingkai Xu, Ling Wang, Maohua Zheng
wiley   +1 more source

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

Drug Design, Development and Therapy, 2012
Georg Golor1, Ke Hu2, Matthieu Ruffin3, Alexandra Buchelt3, Emmanuel Bouillaud3, Yanfeng Wang2, Mario Maldonado31Parexel International GmbH, Berlin, Germany; 2Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Novartis Pharma AG, Basel ...
Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M   +6 more
doaj